Up-regulation of transforming growth factor-beta3 and extracellular matrix proteins in acquired reactive perforating collagenosis.
BACKGROUND
Acquired reactive perforating collagenosis (ARPC) is an uncommon itchy dermatosis of unknown etiology.


OBJECTIVE
We aimed to study clinical features of ARPC and to characterize the expression profiles of proteins which are involved in extracellular matrix remodeling and wound repair.


METHODS
Seventeen patients with ARPC were included in the study. Immunohistochemical analyses were performed for CD34, factor VIIIa, vascular endothelial growth factor, matrix metalloproteinase-1 (MMP-1), tissue inhibitor of metalloproteinase-1 (TIMP-1), transforming growth factor-beta3 (TGF-beta3), Smad-3, and Smad-7.


RESULTS
Twelve patients (70.6%) had diabetes mellitus with disease duration of 14.6 +/- 13.1 years (mean +/- standard deviation). In all patients, chronic kidney disease was evident; two patients were receiving hemodialysis. Preexisting scabies infection was observed in 7 patients (41.2%). CD34 staining was significantly stronger in vessels of perilesional than those of lesional skin (P = .024). TGF-beta3, MMP-1, and TIMP-1 immunoreactivity was significantly stronger in lesional skin as compared with perilesional skin (P = .016, P = .0065, and P = .035, respectively). Although Smad-3 and Smad-7 immunoreactivity did not significantly differ in lesional and perilesional skin, there was a significant correlation between the protein expression of TGF-beta3 and Smad-3 (r = 0.56; P = .02), Smad-7 (r = 0.64; P = .006), and TIMP-1 (r = 0.56; P = .018) expression.


CONCLUSIONS
We did not perform polymerase chain reaction studies on mRNA expression.


CONCLUSIONS
Our clinical data indicate that ARPC is etiopathogenetically linked to chronic kidney disease. Overexpression of TGF-beta3 and extracellular matrix proteins may represent antecedent tissue repair and therefore may be considered a significant event in the resolution of ARPC lesions.
Gambichler
Thilo
T
Department of Dermatology, Ruhr-University of Bochum, Bochum, Germany. t.gambichler@klinikum-bochum.de
Birkner
Lukas
L
Stücker
Markus
M
Othlinghaus
Nick
N
Altmeyer
Peter
P
Kreuter
Alexander
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018952:Antigens, CD34 / Q000378:metabolism; D003095:Collagen Diseases / Q000150:complications / Q000378:metabolism* / Q000473:pathology; D003928:Diabetic Nephropathies / Q000150:complications / Q000378:metabolism*; D016326:Extracellular Matrix Proteins / Q000378:metabolism*; D015944:Factor VIIIa / Q000378:metabolism; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D020781:Matrix Metalloproteinase 1 / Q000378:metabolism; D012871:Skin Diseases / Q000150:complications / Q000378:metabolism* / Q000473:pathology; D051900:Smad3 Protein / Q000378:metabolism; D051906:Smad7 Protein / Q000378:metabolism; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000378:metabolism; D053782:Transforming Growth Factor beta3 / Q000378:metabolism*; D015854:Up-Regulation / Q000502:physiology; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D018952:Antigens, CD34; D016326:Extracellular Matrix Proteins; C497790:SMAD3 protein, human; C497806:SMAD7 protein, human; D051900:Smad3 Protein; D051906:Smad7 Protein; D019715:Tissue Inhibitor of Metalloproteinase-1; D053782:Transforming Growth Factor beta3; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D015944:Factor VIIIa; D020781:Matrix Metalloproteinase 1